Strides Pharma Science Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/e24jm3f93v2gd61zc0085imk.pdf

Key Takeaways


US Business: The Damage and the Rebuild

Arun Kumar: "In the acute therapy, the number of players continue to be few, in which what Strides flourished its strategy, so in the acute whoever dump the product is no more in the market in fact that market has become more attractive for us as a number of players have probably even reduced further."

The Endo Transaction and Portfolio Fix

Arun Kumar: "What the transaction with Endo has done for us has clearly solved what used to be an acute only strategy, which worked very well for us pre-COVID but COVID clearly exposed the portfolio strategy gaps and now with the combined portfolio that we have from Endo and Strides, we do not have any more excuses on our narrowness of our portfolio..."

Margin Recovery Path

Arun Kumar: "I do not see a drop in margins from where we are, but it will not be across the board that we will be able to improve the margins and it is going to take us some time before we get back to our historical 60% gross margin. I mean to be fair US gross margin of 70% and now it is about 60% so getting back to 70% is a long haul and I think somewhere between 60 and 65 we should settle in the US and then kind of recoup at least 3% or 4% of the global gross margins that we have lost in FY2022, and I am quite confident about getting that."

Stelis: CDMO Promise, Sputnik Overhang

Arun Kumar: "Stelis' CDMO business is unique considering that we do not do small contracts. We do service contracts only with supplies, which makes us a very uniquely different biological CDMO compared to other players in the country..."

Balance Sheet and Cash Flow


Guidance & Commitments

CommitmentSpecificsTimeline
US revenueAchieve $250 mn guided revenueFY23
US quarterly run rateApproach $60 mn per quarter"Very soon"
Product launchesMinimum 20 per year, all already approvedStarting now (FY23)
Chestnut Ridge exit run rate$25 mn per quarterFY23
Debt reduction₹1,000 crore (stretched target); at least ₹450 Cr from free cashFY23
Net debt to EBITDA (pharma)Under 2x on run-rate basisFY23 exit
EBITDA margin16–20% rangeFY23 exit
US gross marginSettle between 60% and 65%No timeline (long haul)
Global gross margin recaptureRecoup 3–4% of gross margins lost in FY22No timeline
Stelis CDMO operational breakevenBreak even operationally12–18 months
AmbiVax phase 3 data submissionSubmit final clinical data to Government of IndiaMid-June 2022
Sputnik inventory solutionFind a solutionNext two quarters (critical)

Key Metrics

MetricQ4 FY22
Revenue₹4.4 cr (US sales), moved from ₹38 cr
US business annual guidance$250 million, expected to be linear through the year
Gross margin decline (FY2022)10% drop in FY2022
US gross margin~60%, down from historical 70%
Global gross margin loss (FY2022)3% to 4%
Operating cost increase (FY2022)16% increase in employee and other expenses
Reported consolidated EBITDA₹46 cr
Exceptional items₹77 cr, one-time in nature
EBITDA margin (Q4 FY22)~5%
EBITDA margin target (exit FY23)16% to 20% range
US revenue deflation (FY2022)$50 million
Price erosion range (FY2022)10% to 35%, varying by product
Debt reduction target₹1,000 cr
Target exit EBITDA run rateUnder 3x debt-to-EBITDA
Net debt-to-EBITDA (pharma, exit run rate)Under 2x
Inventory (Sputnik)~$40 million sale value, 12 months shelf life remaining
Stelis CDMO customers onboarded6 in first year, plus 6 added in Q4 FY22
Stelis supply book~₹10 cr for first years of master service activities
Products from Endo acquisitionOver 150
Products currently launched55 to 60
Planned product launches per year20 minimum
Chestnut Ridge expected exit run rate~$25 million per quarter
Other regulated markets performanceHighest quarter in Q4 FY22
Emerging markets sales reps (French Africa)~160
Logistics cost improvement expected300 bps
Shipping container reduction expected40% to 50% fewer containers to sell same or more dollars
Ibuprofen market share28% to 30%, unchanged since COVID
Maintenance capex~₹100 cr per year for next 2–3 years
Australia partner paymentLast payment, due Dec 31, 2022, accelerated to H1 FY23